Adamas Pharmaceuticals, Inc.
Records under this name other than the patents Adamas Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 11 patents it holds.
Back to Adamas Pharmaceuticals, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,741,343 | Method of Administering Amantadine Prior to a Sleep Period now held by Adamas Pharma, LLC In force · High confidence | In force | High confidence | |
| US 9,867,791 | Method of administering amantadine prior to a sleep period now held by Adamas Pharma, LLC In force · High confidence | In force | High confidence | |
| US 9,867,792 | Method of administering amantadine prior to a sleep period now held by Adamas Pharma, LLC In force · Medium confidence | In force | Medium confidence | |
| US 9,867,793 | Method of administering amantadine prior to a sleep period now held by Adamas Pharma, LLC In force · High confidence | In force | High confidence | |
| US 9,877,933 | Method of administering amantadine prior to a sleep period now held by Adamas Pharma, LLC In force · High confidence | In force | High confidence | |
| US 10,154,971 | Methods of Administering Amantadine now held by Adamas Pharma, LLC In force · High confidence | In force | High confidence | |
| US 12,501,953 | Activewear Garment with Enhanced Traction now held by LZRD Tech, Inc. In force · High confidence | In force | High confidence | |
| US 8,168,209 | Method and Composition for Administering an Nmda Receptor Antagonist to a Subject Term ended Term ended Jul 18, 2026 · High confidence | Term ended | Term ended Jul 18, 2026 | High confidence |
| US 8,796,337 | Composition and Method for Treating Neurological Disease Term ended Term ended Nov 23, 2025 · High confidence | Term ended | Term ended Nov 23, 2025 | High confidence |
| US 8,889,740 | Composition and Method for Treating Neurological Disease Term ended Ended no later than Nov 23, 2025 · Medium confidence | Term ended | Ended no later than Nov 23, 2025 | Medium confidence |